Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial
Background: The benefcial efects of polyphenols have been reported. This study aimed to investigate the efect of
oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics.
Methods: In this double-blind, randomized clinical trial, 44 diabetic patients were selected. Patients were assigned to
the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per
day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting
plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed
using SPSS software.
Results: At the beginning and end of the study, there was no signifcant diference between the two groups regarding anthropometric indices (P>0.05). At the end of the survey, EA supplementation signifcantly reduced FPG, insulin,
IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P<0.05). However, these changes were
not signifcant in the placebo group (P>0.05).
Conclusion: EA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular
complications of diabetes by reducing infammation and insulin resistanc
